References
Referencesarepublicationsthatsupporttheproducts'biologicalactivity.
Boireauetal(1997)ThalidomidereducesMPTP-induceddecreaseinstriataldopaminelevelsinmice.Neurosci.Lett.234123PMID:9364513
Kanbayashietal(1996)Thalidomide,ahypnoticwithimmunemodulatingproperties,increasescataplexyincaninenarcolepsy.Neuroreport71881PMID:8905685
Makonkawkeyoonetal(1993)Thalidomideinhibitsthereplicationofhuman-immunodeficiency-virustype1.Proc.Natl.Acad.Sci.U.S.A.905974PMID:8327469
Zhangetal(2008)Thalidomideinfluencesgrowthandvasculogenicmimicrychannelformationinmelanoma.J.Exp.Clin.CancerRes.2760PMID:18983651
Sampaioetal(1991)Thalidomideselectivelyinhibitstumornecrosisfactorαproductionbystimulatedhumanmonocytes.J.Exp.Med.173699PMID:1997652
MerckIndex129390PMID:
Itoetal(2010)Identificationofaprimarytargetofthalidomideteratogenicity.Science3271345PMID:20223979
Keywords:Thalidomide,supplier,TNF-α,TNF-alpha,synthesis,inhibitors,inhibits,Interleukins,Tumor,Necrosis,Factor-α,Factor-alpha,Cytokines,Signaling,Signalling,teratogen,anti-inflammatory,angiogenesis,cereblon,ubiquitin,E3,ligase,Cytokines,Antiangiogenics,Ubiquitin,E3,Ligases,Ubiquitin,E3,Ligases,TocrisBioscience